A Bi-Institutional Pilot Study to Evaluate the Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With High-Risk WHO Grade II Astrocytomas and Oligo-Astrocytomas.

Trial Profile

A Bi-Institutional Pilot Study to Evaluate the Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With High-Risk WHO Grade II Astrocytomas and Oligo-Astrocytomas.

Completed
Phase of Trial: Phase 0

Latest Information Update: 12 Jul 2017

At a glance

  • Drugs SL 701 (Primary) ; Poly ICLC
  • Indications Astrocytoma; Oligodendroglioma
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 14 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (NCT00795457).
    • 10 Sep 2014 Planned End Date changed from 1 Apr 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov record (NCT00795457).
    • 06 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top